Thomas S. Griffith earned his Ph.D. from Washington University (St. Louis, MO) in 1996 examining the cellular and molecular mechanisms of ocular immune privilege. From 1997-1999, Dr. Griffith was a postdoctoral scientist at Immunex Corporation (Seattle, WA). While at Immunex, Dr. Griffith contributed to the initial characterization of TRAIL (TNF-related apoptosis-inducing ligand). Dr. Griffith moved to the Department of Urology at the University of Iowa in 1999, where he continued his evaluation of TRAIL as an antitumor therapeutic. Since August 2011, Dr. Griffith has been an Associate Professor in the Department of Urology at the University of Minnesota. Dr. Griffith is also a member of the Masonic Cancer Center, the Center for Immunology, and the Microbiology, Immunology, and Cancer Biology Graduate Program at the University of Minnesota.
Tumor immunology, apoptosis The research in my laboratory studies the therapeutic potential of apoptotic cell death in the treatment of cancer. The tumor necrosis family member, TRAIL/Apo-2 ligand, is a potent inducer of tumor cell apoptosis, but is non-toxic against normal cell and tissues, suggesting that TRAIL might be administered as an antitumor therapeutic without the side effects seen with other TNF family members, namely TNF and Fas ligand, and traditional chemotherapeutics.Employment of various gene delivery systems, such as non-replicative viral vectors, is making it possible to administer genes directly into tumors sites in situ. Using this technology, a recombinant, replication-deficient adenoviral vector encoding the full-length TRAIL cDNA (Ad-TRAIL) was developed in the laboratory as a way to induce tumor cell death. Current experiments are investigating the ability of Ad-TRAIL to activate systemic antitumor immunity.Additional studies are investigating the ability of apoptotic cells to influence the immune response. For these studies, we use a number of experimental model of tolerance as well as an experimental model of sepsis.